國立虎尾科技大學 |

Competition Law and Policy in the Japanese Pharmaceutical Sector

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Competition Law and Policy in the Japanese Pharmaceutical Sector/ edited by Akira Negishi, Masako Wakui, Naoko Mariyama.
其他作者:	Mariyama, Naoko.
面頁冊數:	XXI, 245 p. 6 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Private International Law, International and Foreign Law, Comparative Law. -
電子資源:	https://doi.org/10.1007/978-981-16-7814-1
ISBN:	9789811678141

Competition Law and Policy in the Japanese Pharmaceutical Sector
Competition Law and Policy in the Japanese Pharmaceutical Sector[electronic resource] /edited by Akira Negishi, Masako Wakui, Naoko Mariyama. - 1st ed. 2022. - XXI, 245 p. 6 illus.online resource. - Kobe University Monograph Series in Social Science Research,2524-5058. - Kobe University Monograph Series in Social Science Research,.

Preface -- PART I　HEALTHCARE AND PHARMACEUTICALS: INNOVATION AND REGULATION IN JAPAN -- Regulation and Competition in the Pharmaceutical Industry in Japan -- Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Declining Population -- Drug Regulation in Japan -- Collaboration between the Patent System and Pharmaceutical Regulations for Drug-discovery Innovation in Japan -- Corruption and Conflicts of Interest in the Pharmaceutical Market: Regulation of Pharmaceutical Companies’ Gift-giving Practices -- PART II THE JAPANESE ANTIMONOPOLY ACT AND ITS RELATION TO THE PHARMACEUTICAL INDUSTRY -- Antimonopoly Act and Its Application to the Pharmaceutical Industry in Japan -- Horizontal Cooperation and Alliances amongst Pharmaceutical Companies and the Japanese Antimonopoly Act -- Merger Regulations in the Japanese Pharmaceutical Industry -- Pay-for-delay Agreements in Japan -- No Challenge Clauses in the Pharmaceutical Industry in Japan -- Will Authorised Biologics deter Biosimilars? -Utilising JFTC’s expertise in drug pricing -- PART III AN ECONOMIC ANALYSIS OF THE PHARMACEUTICAL INDUSTRY AND TRADE PRACTICES IN JAPAN -- The Pharmaceutical Industry in Japan: A History of Its Development -- Trade Practices in the Japanese Pharmaceutical Market: A Simulation Analysis of Improvement Policies.

This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States. Japan is one of the biggest pharmaceutical markets in the world. With this in mind, the book provides “one-stop shopping” for anyone interested in pharmaceutical regulations in the country. Covering the basics but extending to in-depth explorations of complex problems, this book appeals not only to students and academics, pharmaceutical companies and regulators, but also to those dealing with real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation. Chapter 11 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.

ISBN: 9789811678141

Standard No.: 10.1007/978-981-16-7814-1doiSubjects--Topical Terms:

1365811
Private International Law, International and Foreign Law, Comparative Law.

LC Class. No.: K1001-1395

Dewey Class. No.: 346.07

Competition Law and Policy in the Japanese Pharmaceutical Sector
LDR:04595nam a22004095i 4500 001 1094079
003 DE-He213
005 20220429033523.0
007 cr nn 008mamaa
008 221228s2022 si | s |||| 0|eng d
020 $a 9789811678141 $9 978-981-16-7814-1
024 7 $a 10.1007/978-981-16-7814-1 $2 doi
035 $a 978-981-16-7814-1
050 4 $a K1001-1395
072 7 $a LNCB $2 bicssc
072 7 $a LAW014000 $2 bisacsh
072 7 $a LNCB $2 thema
082 0 4 $a 346.07 $2 23
245 1 0 $a Competition Law and Policy in the Japanese Pharmaceutical Sector $h [electronic resource] / $c edited by Akira Negishi, Masako Wakui, Naoko Mariyama.
250 $a 1st ed. 2022.
264 1 $a Singapore : $b Springer Nature Singapore : $b Imprint: Springer, $c 2022.
300 $a XXI, 245 p. 6 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Kobe University Monograph Series in Social Science Research, $x 2524-5058
505 0 $a Preface -- PART I　HEALTHCARE AND PHARMACEUTICALS: INNOVATION AND REGULATION IN JAPAN -- Regulation and Competition in the Pharmaceutical Industry in Japan -- Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Declining Population -- Drug Regulation in Japan -- Collaboration between the Patent System and Pharmaceutical Regulations for Drug-discovery Innovation in Japan -- Corruption and Conflicts of Interest in the Pharmaceutical Market: Regulation of Pharmaceutical Companies’ Gift-giving Practices -- PART II THE JAPANESE ANTIMONOPOLY ACT AND ITS RELATION TO THE PHARMACEUTICAL INDUSTRY -- Antimonopoly Act and Its Application to the Pharmaceutical Industry in Japan -- Horizontal Cooperation and Alliances amongst Pharmaceutical Companies and the Japanese Antimonopoly Act -- Merger Regulations in the Japanese Pharmaceutical Industry -- Pay-for-delay Agreements in Japan -- No Challenge Clauses in the Pharmaceutical Industry in Japan -- Will Authorised Biologics deter Biosimilars? -Utilising JFTC’s expertise in drug pricing -- PART III AN ECONOMIC ANALYSIS OF THE PHARMACEUTICAL INDUSTRY AND TRADE PRACTICES IN JAPAN -- The Pharmaceutical Industry in Japan: A History of Its Development -- Trade Practices in the Japanese Pharmaceutical Market: A Simulation Analysis of Improvement Policies.
520 $a This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States. Japan is one of the biggest pharmaceutical markets in the world. With this in mind, the book provides “one-stop shopping” for anyone interested in pharmaceutical regulations in the country. Covering the basics but extending to in-depth explorations of complex problems, this book appeals not only to students and academics, pharmaceutical companies and regulators, but also to those dealing with real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation. Chapter 11 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
650 2 4 $a Private International Law, International and Foreign Law, Comparative Law. $3 1365811
650 2 4 $a Law and Economics. $3 669261
650 2 4 $a Health Care. $3 1365997
650 2 4 $a IT Law, Media Law, Intellectual Property. $3 1209939
650 2 4 $a Medical Law. $3 671732
650 1 4 $a Commercial Law. $3 669651
650 0 $a Comparative law. $3 560198
650 0 $a International law. $3 557047
650 0 $a Conflict of laws. $3 560163
650 0 $a Private international law. $3 1202562
650 0 $a Law and economics. $3 560301
650 0 $a Medical care. $3 654242
650 0 $a Mass media—Law and legislation. $3 1388060
650 0 $a Information technology—Law and legislation. $3 1388059
650 0 $a Medical laws and legislation. $3 567375
650 0 $a Commercial law. $3 560158
700 1 $a Mariyama, Naoko. $e editor. $1 https://orcid.org/0000-0002-2834-5073 $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1402138
700 1 $a Wakui, Masako. $e editor. $1 https://orcid.org/0000-0001-5277-1606 $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1402137
700 1 $a Negishi, Akira. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1402136
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811678134
776 0 8 $i Printed edition: $z 9789811678158
776 0 8 $i Printed edition: $z 9789811678165
830 0 $a Kobe University Monograph Series in Social Science Research, $x 2524-504X $3 1306433
856 4 0 $u https://doi.org/10.1007/978-981-16-7814-1
912 $a ZDB-2-LCR
912 $a ZDB-2-SXLC
950 $a Law and Criminology (SpringerNature-41177)
950 $a Law and Criminology (R0) (SpringerNature-43727)